Search for pathogenesis and novel therapeutics of hematological malignancies based on generation of iPS cells from primary tumor cells

Research Project Outline

Primary tumor cells from patients with hematological malignancies are ideal sources for the research of pathogenesis and therapeutics, but it is often difficult to obtain them sufficiently. In this study, we reprogram patient-derived tumor cells into iPSCs and expand them through re-differentiation into hematopoietic cells. Using these cells, we perform extensive studies which require a large number of living cells such as epigenomics, proteomics, functional genomics, and drug screening. Through these analyses, we aim to elucidate disease mechanisms and establish novel targeted therapies for hematological malignancies.